Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05565105Phase 2Not Yet Recruiting

CD34+ Transplants for Leukemia and Lymphoma

Role: lead

NCT05617625Phase 2Suspended

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Role: lead

NCT05350163Phase 1Terminated

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Role: lead

NCT04982354Phase 1Withdrawn

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Role: lead

All 4 trials loaded